HOME >> BIOLOGY >> NEWS
Key stimulator of colorectal cancer identified

A new research study identifies a molecule that promotes one of the most deadly cancers in humans and reveals the molecular mechanisms underlying the protective effects of nonsteroidal anti-inflammatory drugs (NSAIDS) against the disease. The research, published in the September issue of Cancer Cell, identifies potential targets for future therapeutics aimed at the prevention and treatment of cancer of the colon and rectum.

Colorectal cancer (CRC) is the second most common cause of death due to cancer for men and women in the United States It has been known for some time that NSAIDS and other cyclooxygenase (COX) inhibitors reduce the risk of CRC. However, the exact mechanisms of this protective action are unclear. PGE2 is a metabolite of COX that is elevated in CRC and has been implicated in disease development and progression. Peroxisome proliferator-activated receptor d (PPARd), a regulator of cell survival, has also been linked to CRC. Dr. Raymond N. DuBois from the Department of Medicine at Vanderbilt University Medical Center and Vanderbilt-Ingram Cancer Center in Nashville, Tennessee and colleagues investigated whether the ability of PGE2 to promote CRC is dependent on PPARd.

The researchers found that PGE2 indirectly activates PPARd via a signaling pathway that promotes cell survival and polyp formation. Polyps are abnormal growths in the colon and rectum that are believed to be an early stage of CRC. In a mouse model system for studying polyp formation, PGE2 treatment induced an increase in the number and size of intestinal polyps. Importantly, this effect of PGE2 was not observed in these mice when they lack PPARd.

"Our results identify PPARd as a critical downstream mediator in PGE2-stimulated promotion of colorectal tumor growth," says Dr. DuBois. "They suggest that PPARd is an important pro-cancer factor in CRC, and that agents which stimulate PPARd may encourage abnormal cell growth in certain populations at risk for CRC.
'"/>

Contact: Heidi Hardman
hhardman@cell.com
617-397-2879
Cell Press
20-Sep-2004


Page: 1 2

Related biology news :

1. Milk consumption and calcium intake associated with lower colorectal cancer risk
2. Researchers identify genetic markers to predict response to chemotherapy for colorectal cancer
3. Study links diabetes and colorectal cancer
4. Drug that cuts off tumors blood supply extends lives of colorectal cancer patients
5. Researchers begin promising new trial to fight colorectal cancer
6. Revised guidelines published for testing for hereditary type of colorectal cancer
7. Mount Sinai School of Medicine conducting clinical trials with gene therapy for colorectal cancer
8. BRCA mutations not associated with colorectal cancer risk, studies suggest
9. BRCA mutations do not increase risk of colorectal cancer
10. Older drug could have exciting new role in treating colorectal cancer
11. New findings suggest colorectal cancer origins are different than previously thought

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/20/2019)... , ... November 20, 2019 , ... BioInformatics Inc., part ... science tools market, today announced the winners of the Life Science Industry Awards for ... the Life Science Industry Awards – Innovation: , Most Innovative New Product – Cell ...
(Date:11/19/2019)... ... November 19, 2019 , ... Diagenode, Inc., ... Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science ... offer Single-Cell ATAC-Seq (scATAC-Seq) Services, featuring Bio-Rad’s Droplet Digital PCR technology, to help ...
(Date:11/19/2019)... ... ... Hosted at the Las Vegas Convention Center, and brought to you by ... of MJBiz business professionals in the world. With over 1,300 exhibitors from more than ... show quite like it. Atlantic Ultraviolet will exhibit at Booth C9217, showcasing its ...
Breaking Biology News(10 mins):
(Date:12/4/2019)... N.C. (PRWEB) , ... December 03, 2019 , ... A ... studies have shown can reduce and even reverse fibrosis (scar tissue) buildup – also ... at Stanford University School of Medicine, was conducted on mice. , The tumor-destroying ...
(Date:11/22/2019)... ... November 22, 2019 , ... Modality Solutions, ... cold chain validation guide to meet and exceed increasingly stringent regulatory expectations ... biopharmaceutical industry leaders, the September 19, 2019 webinar was well received and ...
(Date:11/12/2019)... ... November 12, 2019 , ... ... software solutions for biopharmaceutical R&D, today announced that Immatics Biotechnologies , ... Genedata Biologics® to streamline their R&D operations related to the ...
(Date:11/6/2019)... ... 2019 , ... Diversified Technologies, Inc. has introduced a PEF production ... to improve processing. , The DTI Industrial PEF Unit can pre-treat whole pieces of ... yields by up to 50% and achieve up to an 80% reduction of drying ...
Breaking Biology Technology:
Cached News: